<DOC>
	<DOC>NCT00761631</DOC>
	<brief_summary>This open-label, multicenter study is designed to evaluate the safety, tolerability and immunogenicity of 13-valent pneumococcal conjugate vaccine in healthy children aged more than 15 months up to less than 18 years.</brief_summary>
	<brief_title>Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male or female subjects &gt;15months to &lt;18years in good health, available for entire study period and reachable by phone, parents/legal guardian able and willing to complete all study procedures, written documentation from health professional showing prior vaccination with Prevnar (except for group 4). Group 4 only: Negative urine pregnancy test for female subjects who are menstruating. Previous reaction or contraindication to pneumococcal vaccine or vaccine related component , bleeding diathesis, received blood transfusion or blood related products, immune deficiency,congenital malformation. Group 4 only: Previous vaccination with Prevnar or any other pneumococcal vaccine. Pregnant or breastfeeding adolescent females.</criteria>
	<gender>All</gender>
	<minimum_age>15 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>